At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 403 enrolled
Drug / intervention
BMS-986278 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
In Brief
A Phase 2 clinical trial evaluating BMS-986278 Placebo and BMS-986278 for Pulmonary Fibrosis. Completed, enrolled 403 participants across 119 sites in 18 countries.
Detailed Summary
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Fibrosis
CountriesArgentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Japan, Mexico, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartJul 2020
Primary CompletionAug 2022
Study CompletionSep 2023
TodayJul 2026
First PostedMar 16, 2020
Enrollment StartJul 29, 2020
Primary CompletionAug 4, 2022
Study CompletionSep 22, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.3 years ago
Interventions
BMS-986278 Placeboother
Specified Dose on Specified Days
BMS-986278drug
Specified Dose on Specified Days